The 5-year CCSS of the colon cancer patients with low PROX1 expression was 62% (95% CI, 55.2–68.9%), as compared with 47% for those with high staining intensity (95% CI, 35.3–59.0%). Here, PROX1 is linked to colonic neoplasm.